The drug received a priority review because of its significant potential benefit to public health. Chantix was reviewed in six months rather than the regular review time of 10 months, says Curt Rosebraugh, M.D., M.P.H., deputy director of the FDA's Office of Drug Evaluation H. "Chantix...
WASHINGTON, Oct. 17 (Xinhua) -- American scientists identified a potential new smoking quit treatment in rodents, according to a study published on Wednesday in the journal Science Advances. Researchers at Scripps Research gave nicotine-dependent rats an engineered enzyme that broke down nicotine in ...
Smokers encounter several difficulties when they try to quit. Nicotine is a potent psychoactive drug that causes physical dependence [7], and withdrawal symptoms put patients at risk for early relapse. Post-cessational weight gain is another substantial barrier [8]. On average, people who quit s...
Bupropion is the first new pharmacological treatment for smokers to be introduced since nicotine replacement therapy 20 years ago. Bupropion can potentially have a huge impact on public health not only through the efficacy of the drug itself but also by making smoking cessation services more widely ...
Current drug therapy concentrates on bronchodilators to reduce symptoms, and the new long-acting anticholinergic tiotropium bromide seems to be the most effective bronchodilator to date. No treatment is available at present that stops the relentless progression of the disease. A better understanding of...
Drug and Alcohol Dependence, 198, 105–111. https://doi.org/10.1016/j.drugalcdep.2019.01.041 National Academies of Sciences, Engineering, and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies ...
Even though new drugs will help to improve the prognosis of people with DKD, it becomes more and more a challenge for physicians to choose the most beneficial medication or combination of medications for an individual patient. There is a need to evaluate the kidney-protective effects of ...
The U.S. Food and Drug Administration Friday called for increased awareness of the health risks of the smoking cessation drug varenicline. The agency said it appears increasingly likely that there may be an association between the drug, marketed by Pfizer under the name Chantix, and serious neuro...
Altered muscarinic acetylcholine receptor (mAChR) activity is implicated in many disorders including Alzheimer's disease, schizophrenia, pain, obesity and diabetes, but lack of knowledge of the precise functional roles of the individual mAChR subtypes has hampered drug development. Wess and colleagues re...
given that Pfizer's main patent for vareniclineexpired in 2020, there is less financial incentive for them to remedy the situation and resume production. When a patent expires, other pharmaceutical companies are free to make "generic" copies of the drug—usually at ...